Population genetic screening for haemochromatosis: Identifying asymptomatic “at risk” homozygous individuals.
© Commonwealth of Australia 2005

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney General’s Department, Robert Garran Offices, National Circuit, Canberra ACT 2600 or posted at http://www.ag.gov.au/cca

Electronic copies can be obtained from http://www.horizonscanning.gov.au

Enquiries about the content of these summaries should be directed to:

HealthPACT Secretariat
Department of Health and Ageing
MDP 106
GPO Box 9848
Canberra ACT 2606
AUSTRALIA

DISCLAIMER: These summaries are based on information available at the time of research and cannot be expected to cover any developments arising from subsequent improvements to health technologies. These summaries are based on a limited literature search and are not a definitive statement on the safety, effectiveness or cost-effectiveness of the health technology covered.

The Commonwealth does not guarantee the accuracy, currency or completeness of the information in these summaries. These summaries are not intended to be used as medical advice and are not intended to be used to diagnose, treat, cure or prevent any disease, nor should they be used for therapeutic purposes or as a substitute for a health professional's advice. The Commonwealth does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information.

The production of these Horizon scanning prioritising summaries was overseen by the Health Policy Advisory Committee on Technology (HealthPACT), a sub-committee of the Medical Services Advisory Committee (MSAC). HealthPACT comprises representatives from health departments in all states and territories, the Australia and New Zealand governments; MSAC and ASERNIP-S. The Australian Health Ministers’ Advisory Council (AHMAC) supports HealthPACT through funding.

These Horizon scanning prioritising summaries were prepared by Linda Mundy and Tracy Merlin from the National Horizon Scanning Unit, Adelaide Health Technology Assessment, Department of Public Health, Mail Drop 511, University of Adelaide, South Australia, 5005.
NAME OF TECHNOLOGY: POPULATION GENETIC SCREENING FOR HAEMOCHROMATOSIS

PURPOSE AND TARGET GROUP: IDENTIFYING ASYMPTOMATIC “AT RISK” HOMOZYGOUS INDIVIDUALS

STAGE OF DEVELOPMENT (IN AUSTRALIA):
Genetic Testing for haemochromatosis is established technology, however population screening is not current policy.

- Yet to emerge
- Experimental
- Investigational
- Nearly established
- Established
- Established but changed indication or modification of technique
- Should be taken out of use

AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION APPROVAL

- Yes
- No
- Not applicable

INTERNATIONAL UTILISATION OF SCREENING FOR HAEMOCHROMATOSIS:

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>LEVEL OF USE</th>
<th>Trials Underway or Completed</th>
<th>Limited Use</th>
<th>Widely Diffused</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>United States</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

IMPACT SUMMARY:
The Medicare Benefits Schedule (MBS) provides item number 66794 with the aim of detecting the genetic mutation responsible for haemochromatosis, if patients have an elevated transferrin saturation or elevated serum ferritin, or a first degree relative with haemochromatosis; or a first degree relative with homozygosity for the C282Y genetic mutation. The technology is available through private and public pathology providers for individuals considered at risk of hereditary haemochromatosis (HH).

Individuals who are homozygous for a single mutation (C282Y) in the HFE are at risk of developing iron overload and subsequent haemochromatosis. Approximately 60% of C228Y homozygotes develop iron overload but it is unknown what proportion of these patients will go on to develop serious disease. Iron accumulation can damage the heart, liver, pancreatic islets and other tissues. Undetected cases can lead to cirrhosis of the liver, hepatic malignancy, heart failure or diabetes mellitus. Phlebotomy is a safe, effective and acceptable treatment, with possible benefits for the population at large due to the increase in the blood donor population. Early detection and therefore early treatment avoids the sequelae of the disease. A population based screening study in Australia (Olynyk et al 1999) found 0.5% of screened individuals were homozygote for C228Y and half of these individuals presented with clinical features of haemochromatosis. The number of claims processed by HIC for the
MBS item number 66794 has increased from 17,995 in the period July 1999 – June 2000, to 31,583 for the period July 2002 – June 2003.

A number of studies have found screening for HH to be cost-effective but this would require further research in the Australian setting.

**CONCLUSION:**
Population screening for haemochromatosis has not been assessed, however use of the MBS item number (66794) is increasing and it is showing signs of rapidly diffusing throughout the Australian health system. Limited prevalence studies indicate that population screening for HH has the potential to deliver both long and short-term benefits.

**HEALTHPACT ACTION:**
Therefore it is recommended that this technology be referred to the Pathology Services Tables Committee.

**SOURCES OF FURTHER INFORMATION:**

**SEARCH CRITERIA TO BE USED:**
Hemochromatosis/epidemiology/*genetics/*prevention & control
Mass screening
Sensitivity-and-specificity
Predictive-value-of –tests
Homozygote
Prevalence